429
Participants
Start Date
December 31, 2006
Primary Completion Date
April 30, 2010
Study Completion Date
June 30, 2013
Octreotide
Octreotide 30 mg intramuscularly (i.m.) every 28 days.
Placebo
A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
Everolimus
A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.
Novartis Investigative Site, Brussels
Novartis Investigative Site, Kogarah
Novartis Investigative Site, Herston
Novartis Investigative Site, South Brisbane
New York University Medical Center NYU Medical Center (2), New York
New York Oncology Hematology, P.C. Dept. of New York Oncology. PC, Albany
Novartis Investigative Site, Berlin
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Novartis Investigative Site, Hamburg
Virginia Oncology Associates VOA - Lake Wright, Norfolk
Duke University Medical Center Dept. of Duke Cancer Center, Durham
Novartis Investigative Site, Madrid
Cancer Centers of the Carolinas CC of C -Eastside, Greenville
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Montpellier
Ocala Oncology Center Dept. of Ocala Oncology Center, Ocala
Novartis Investigative Site, Bologna
Norton Cancer Institute Clinical Research Program, Louisville
Indiana University Dept.of IndianaUniv.CancerCtr, Indianapolis
Central Indiana Cancer Centers CICC - South, Indianapolis
University of Iowa Medical Center Internal Medicine, Iowa City
University of Wisconsin / Paul P. Carbone Comp Cancer Center GI Oncology Research Center, Madison
Mayo Clinic - Rochester Division of Hematology, Rochester
Novartis Investigative Site, Pisa
Novartis Investigative Site, Lille
Cancer Care and Hematology Specialists of Chicagoland Niles, Niles
Washington University School Of Medicine-Siteman Cancer Ctr Division of Oncology, St Louis
The Center for Cancer Care and Research, St Louis
University of Kansas Cancer Center Deptof Uof Kansas CancerCenter, Kansas City
Kansas City Cancer Center KCCC Business Office, Overland Park
Novartis Investigative Site, Strasbourg
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Deptof LSU Health Sciences (2), New Orleans
Hematology Oncology Services of Arkansas, Little Rock
Highlands Oncology Group The Center for Chest Care, Fayetteville
Sammons Cancer Center - Texas Oncology Sammons Cancer Center (SC), Dallas
Tyler Cancer Center, Tyler
Novartis Investigative Site, Paris
Texas Oncology, P.A. Forth Worth -- 12th Avenue, Fort Worth
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology, Houston
South Texas Institute of Cancer S. Tex Inst.- Corpus Christi, Corpus Christi
Texas Oncology, P.A. Central Austin Cancer Center, Austin
University of Colorado Dept. of Univ. of Colorado, Aurora
Rocky Mountain Cancer Centers Dept of Rocky Mountain (2), Denver
University of Arizona / Arizona Cancer Center Deptof Uof A/Arizona Cancer(2), Tucson
Cedars Sinai Medical Center SC-2, Los Angeles
University of California at Los Angeles UCLA New SC Address, Los Angeles
Novartis Investigative Site, Clichy Cédex
Pacific Cancer Medical Center, Inc., Anaheim
Novartis Investigative Site, Villejuif
Northwest Cancer Specialists Compass Oncology -BKM, Vancouver
Eastern Connecticut Hematology & Oncology Associates Dept. of ECHO, Norwich
Cancer Centers of Connecticut Southington Location, Southington
Hematology Oncology PC Dept.of Hematology Oncology(2), Stamford
Dartmouth Hitchcock Medical Center Medical Oncology, Lebanon
Fox Chase Cancer Center, Philadelphia
Novartis Investigative Site, London
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Montreal
Novartis Investigative Site, Prague
Novartis Investigative Site, Příbram
Novartis Investigative Site, Helsinki
Novartis Investigative Site, Athens
Novartis Investigative Site, Perugia
Novartis Investigative Site, Groningen
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Bratislava
Novartis Investigative Site, Uppsala
Novartis Investigative Site, Basingstoke
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY